Literature DB >> 15075139

Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia.

Keith Wheatley1, Richard Gray.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15075139     DOI： 10.1093/ije/dyg313

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN： 0300-5771            Impact factor:   7.196


× No keyword cloud information.
  21 in total

Review 1.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

2.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

Review 3.  Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?

Authors:  Shah Ebrahim; George Davey Smith
Journal:  Hum Genet       Date:  2007-11-23       Impact factor: 4.132

Review 4.  Capitalizing on Mendelian randomization to assess the effects of treatments.

Authors:  George Davey Smith
Journal:  J R Soc Med       Date:  2007-09       Impact factor: 5.344

Review 5.  Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

Authors:  Ehab Atallah; Kathryn Bylow; Jesse Troy; Wael Saber
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 6.  Where GWAS and epidemiology meet: opportunities for the simultaneous study of genetic and environmental risk factors in schizophrenia.

Authors:  John J McGrath; Preben Bo Mortensen; Peter M Visscher; Naomi R Wray
Journal:  Schizophr Bull       Date:  2013-08-01       Impact factor: 9.306

7.  Treatment of acute myeloid leukemia in the elderly.

Authors:  Elihu H Estey
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

8.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

9.  Recent developments in management of older patients with acute myeloid leukemia.

Authors:  Elihu Estey
Journal:  Ther Adv Hematol       Date:  2012-04

Review 10.  Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Authors:  Max Schlaak; Juliane Pickenhain; Sebastian Theurich; Nicole Skoetz; Michael von Bergwelt-Baildon; Peter Kurschat
Journal:  Cochrane Database Syst Rev       Date:  2013-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.